These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 21623918)

  • 21. Practical use of azacitidine in higher-risk myelodysplastic syndromes: an expert panel opinion.
    Fenaux P; Bowen D; Gattermann N; Hellström-Lindberg E; Hofmann WK; Pfeilstöcker M; Sanz G; Santini V
    Leuk Res; 2010 Nov; 34(11):1410-6. PubMed ID: 20609474
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Azacitidine: activity and efficacy as an epigenetic treatment of myelodysplastic syndromes.
    Santini V
    Expert Rev Hematol; 2009 Apr; 2(2):121-7. PubMed ID: 21083445
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The prognostic value of circulating myeloblasts in patients with myelodysplastic syndromes treated with azacitidine.
    Kamiya T; Nakazato T
    Med Oncol; 2019 Jan; 36(3):25. PubMed ID: 30706221
    [No Abstract]   [Full Text] [Related]  

  • 24. Azacitidine.
    Issa JP; Kantarjian HM; Kirkpatrick P
    Nat Rev Drug Discov; 2005 Apr; 4(4):275-6. PubMed ID: 15861567
    [No Abstract]   [Full Text] [Related]  

  • 25. Myelodysplastic syndromes (MDS).
    Klimek V
    Best Pract Res Clin Haematol; 2015 Mar; 28(1):1-2. PubMed ID: 25659724
    [No Abstract]   [Full Text] [Related]  

  • 26. Treatment of myelodysplastic syndrome: questions raised by the azacitidine experience.
    Kantarjian HM
    J Clin Oncol; 2002 May; 20(10):2415-6. PubMed ID: 12011118
    [No Abstract]   [Full Text] [Related]  

  • 27. Bioavailability of azacitidine subcutaneous versus intravenous in patients with the myelodysplastic syndromes.
    Marcucci G; Silverman L; Eller M; Lintz L; Beach CL
    J Clin Pharmacol; 2005 May; 45(5):597-602. PubMed ID: 15831784
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Atraumatic splenic rupture in patients with myelodysplastic syndromes: report of a case occurred during treatment with 5-azacitidine and review of the literature.
    Forghieri F; Morselli M; Leonardi G; Potenza L; Bonacorsi G; Coluccio V; Paolini A; Maccaferri M; Colaci E; Fantuzzi V; Bigliardi S; Zaldini P; Riva G; Barozzi P; Leonardi L; Rossi A; Marasca R; Narni F; Luppi M
    Leuk Res; 2012 Mar; 36(3):e52-6. PubMed ID: 22172466
    [No Abstract]   [Full Text] [Related]  

  • 29. Azacitidine. Poor-prognosis myelodysplasia: promising, but more data needed.
    Prescrire Int; 2011 Feb; 20(113):40. PubMed ID: 21488589
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interstitial lung disease associated with azacitidine use: a case report.
    Sekhri A; Palaniswamy C; Kurmayagari K; Kalra A; Selvaraj DR
    Am J Ther; 2012 Mar; 19(2):e98-e100. PubMed ID: 20634671
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Effectiveness and safety of 5-azacitidine in three patients with myelodysplastic syndromes].
    Garzás-Martín de Almagro MC; Gago Sánchez AI; Cuevas Asencio I; Reyes Malia M
    Farm Hosp; 2010; 34(4):204-8. PubMed ID: 20185350
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic significance of monosomal karyotype in higher risk myelodysplastic syndrome treated with azacitidine.
    Itzykson R; Thépot S; Eclache V; Quesnel B; Dreyfus F; Beyne-Rauzy O; Turlure P; Vey N; Recher C; Boehrer S; Gardin C; Adès L; Fenaux P;
    Leukemia; 2011 Jul; 25(7):1207-9. PubMed ID: 21468040
    [No Abstract]   [Full Text] [Related]  

  • 33. Advances in myelodysplastic syndrome: nursing implications of azacitidine.
    Demakos EP; Linebaugh JA
    Clin J Oncol Nurs; 2005 Aug; 9(4):417-23. PubMed ID: 16117208
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neutrophilic panniculitis following azacitidine treatment for myelodysplastic syndromes.
    Kim IH; Youn JH; Shin SH; Yahng SA; Lee SE; Kwon JC; Lee DG; Park KS; Choi MH; Jung SE; Kim YJ
    Leuk Res; 2012 Jul; 36(7):e146-8. PubMed ID: 22483068
    [No Abstract]   [Full Text] [Related]  

  • 35. 5-azacitidine: An alternative treatment of myelodysplastic syndromes in patient with refractory response to hematopoietic growth factor, a case report and review of literatures.
    Suwanawiboon B; Sumida KN
    Hawaii Med J; 2004 Jan; 63(1):14-6, 25. PubMed ID: 15011897
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A new prognostic index to make short-term prognoses in MDS patients treated with azacitidine: A combination of p53 expression and cytogenetics.
    Nishiwaki S; Ito M; Watarai R; Okuno S; Harada Y; Yamamoto S; Suzuki K; Kurahashi S; Iwasaki T; Sugiura I
    Leuk Res; 2016 Feb; 41():21-6. PubMed ID: 26651421
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intravenous azacitidine for MDS.
    Gore SD
    Clin Adv Hematol Oncol; 2007 Mar; 5(3):234. PubMed ID: 17519884
    [No Abstract]   [Full Text] [Related]  

  • 38. Myelodysplastic syndromes: emerging therapies, survival, and alternative outcomes.
    Scott BL
    Manag Care; 2009 Nov; 18(11 Suppl 9):4-12; discussion 13-4. PubMed ID: 20085111
    [No Abstract]   [Full Text] [Related]  

  • 39. Effectiveness of azacitidine for the treatment of higher-risk myelodysplastic syndromes in daily practice: the authors' reply.
    Bernal T; Martínez-Camblor P; Sánchez-García J; Sanz G
    Leukemia; 2016 Mar; 30(3):740-1. PubMed ID: 26754826
    [No Abstract]   [Full Text] [Related]  

  • 40. DNA methylation profiling of myelodysplastic syndromes and clinical response to azacitidine: A multicentre retrospective study.
    Noguera-Castells A; Campillo-Marcos I; Davalos V; García-Prieto CA; Valcárcel D; Molero A; Palomo L; Gattermann N; Wulfert M; Chaparro-González L; Solé F; Cabezón M; Jiménez-Lorenzo MJ; Xicoy B; Zamora L; De Stefano A; Casalin I; Finelli C; Follo MY; Esteller M
    Br J Haematol; 2024 May; 204(5):1838-1843. PubMed ID: 38471524
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.